Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

This image opens in the lightbox

News provided by

Zifo Technologies

14 Aug, 2025, 12:30 GMT

Share this article

Share toX

Share this article

Share toX

Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake

CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14, 2025 /PRNewswire/ -- Zifo announced the launch of its Antibody Engineering application, a cloud-native GenAI platform built on the Snowflake Data Cloud and available on the Snowflake Marketplace, which empowers biopharma companies, research institutions, and contract research organizations to design and optimize therapeutic antibodies faster and potentially shortening the timeline for new drug discovery without needing to move data outside of Snowflake.

Continue Reading
This image opens in the lightbox
Zifo's cloud-native, scalable solution allows users to go from input to insight within a single integrated platform. Three open-source models -- from ProtGPT2 to ESM and RoBERTa -- are supported, hence teams aren’t locked into one approach. This mitigates model selection challenges by enabling side-by-side benchmarking and tailored model use within a single, adaptable environment.

The development of new antibody-based therapies is traditionally a complex, time-consuming, and expensive process. Zifo's Antibody Engineering app directly confronts this challenge by integrating state-of-the-art AI into a seamless, end-to-end workflow that promises to improve the hit rate for high-affinity therapeutic antibodies.

"We are entering a new era of drug discovery, one where AI and data converge to solve biology's most complex puzzles," said Chris McClure, Head of Solution Services for Zifo in North America. "Zifo Antibody Engineering is more than just a tool; it's a strategic partner for scientists. By building it as a Snowflake Native App, we're giving researchers the power to innovate faster, reduce R&D costs, and ultimately bring life-saving therapies to patients sooner. We've effectively democratized access to complex AI, removing the need for deep machine learning expertise."

Leveraging the power and scalability of Snowflake's platform, including Snowpark Container Services, the application provides a no-code, intuitive interface for scientists and bioinformaticians. Users can fine-tune powerful protein language models like ProtGPT2, RoBERTa, and ESM2 on their proprietary datasets without moving sensitive information outside of their secure Snowflake environment. The platform facilitates the entire discovery pipeline, from generating novel antibody sequences to predicting their 3D structures and analyzing key regions.

"Zifo Antibody Engineering, combined with Snowflake's infrastructure, offers life sciences a cutting-edge tool for research development," said Lisa Arbogast, Industry Principal for Healthcare and Life Sciences Ecosystem at Snowflake. "Together, we enable use of data to its fullest potential while helping customers adhere to high standards of security and compliance."

The value of Zifo's Antibody Engineering platform extends across the life sciences ecosystem:

  • Biopharma R&D Teams: Streamline antibody discovery by generating novel sequences and predicting binding affinities faster than traditional methods.
  • CDMOs and CROs: Offer AI-powered protein engineering as a service to clients developing therapeutic antibodies.
  • Academic and Research Institutions: Leverage advanced protein modeling tools to push the boundaries of computational biology and structural bioinformatics.
  • Clinical and Preclinical Development: Validate AI-generated antibodies with experimental data, expediting lead selection.

The architecture is designed for high-performance AI workloads, handling massive datasets and multi-modal inputs with ease, all within Snowflake's managed environment. After fine-tuning models, users can generate new antibody sequences, visualize their 3D protein structures, download PDB files, and review analysis of complementarity-determining regions (CDRs).

Zifo's Antibody Engineering App can be downloaded from Snowflake Marketplace here.

To access the Antibody Engineering App Documentation, please click here.

About Zifo 

Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve various industries, including pharma, biotech, chemicals, food and beverage, oil and gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. For more information, visit zifornd.com.

Video: https://www.youtube.com/watch?v=CslVULoKlBU
Logo: https://mma.prnewswire.com/media/2731415/5460327/Zifo_Technologies_Logo.jpg

Modal title

Also from this source

Zifo on AI in Biopharma: Not a Magic Wand, But a Transformative Tool

Zifo on AI in Biopharma: Not a Magic Wand, But a Transformative Tool

As the race to use artificial intelligence (AI) in drug discovery intensifies, Zifo's Sujeegar Jeevanandam cautions that the real power of AI isn't...

Zifo's Global Survey Reveals Early Momentum for AI in Biopharma, But Data Readiness Remains Key Hurdle

Zifo's Global Survey Reveals Early Momentum for AI in Biopharma, But Data Readiness Remains Key Hurdle

A new survey of scientists and informaticians reveals that while investment in artificial intelligence (AI) and machine learning (ML) is rapidly...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Computer & Electronics

Computer & Electronics

Biotechnology

Biotechnology

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.